GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep …
2 days ago · On Thursday, GSK plc (NYSE:GSK) released headline results from a planned interim analysis of the DREAMM-7 head-to-head phase 3 trial of Blenrep (belantamab mafodotin) in combination with ...
GSK's ADC Blenrep delivers survival win against J&J's Darzalex
2 days ago · In boost to GSK's £3B plan for Blenrep, myeloma ADC shows survival edge over J&J's Darzalex. GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears ...
GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep …
2 days ago · The DREAMM-7 trial showed Blenrep with BorDex lowered death risk in relapsed/refractory multiple myeloma vs. standard treatment. A phase 3 study in newly diagnosed transplant-ineligible multiple ...
GSK will pull Blenrep from US market after failed trial
6 days ago · GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US...
GSK announces Blenrep met key secondary endpoint in DREAMM …
3 days ago · GSK announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head phase III trial evaluating Blenrep in combination with bortezomib plus dexamethasone as a ...
Blenrep shows overall survival benefit in head-to-head DREAMM …
3 days ago · About Blenrep. Blenrep is an antibody-drug conjugate comprising a humanised B-cell maturation antigen monoclonal antibody conjugated to the cytotoxic agent auristatin F via a non-cleavable linker. The drug linker technology is licensed from Seagen Inc.; the monoclonal antibody is produced using POTELLIGENT Technology licensed from BioWa Inc., a ...
GSK backs up its Blenrep rehab bid with survival data
5 days ago · GSK has reported data it hopes will allow a return to the US for Blenrep, the first BCMA-targeting drug to launch for multiple myeloma.
After withdrawal, GSK touts another Blenrep combo win as …
Mar 7, 2024 · GSK has more trial evidence to support a potential comeback for its withdrawn antibody-drug conjugate Blenrep. In patients with previously treated multiple myeloma, Blenrep beat Takeda’s...
GSK provides an update on Blenrep (belantamab mafodotin …
Nov 22, 2022 · GSK plc (LSE/NYSE: GSK) today announced it has initiated the process for withdrawal of the US marketing authorisation for Blenrep (belantamab mafodotin-blmf) following the request of the US Food and Drug Administration (FDA).
EU regulator recommends stopping sale of GSK's blood cancer drug
Sep 15, 2023 · The EU drug regulator on Friday recommended against renewing the conditional marketing authorisation for GSK's blood cancer drug Blenrep, which GSK stopped selling in the U.S. last year at the...
- Some results have been removed